



CANCER

ADVANCED PANCREATIC CANCER

OSI (OSIP) AND GENENTECH (DNA)

A BIG CONGRATULATION

We cannot believe our ears and eyes, learning 24 hours ago only that OSIP and DNA becoming subject to downgrade, with OSIP reaching the bottom of its price, based on prediction (false of course) that the Oncologic Drug Advisory Committee (ODAC) appointed by the FDA would vote against **recommending approval of Tarceva® (erlotinib) for pancreatic cancer. Yesterday, the Committee did vote.**

Guess what? It voted 10 to 3 in favor of approving the drug in combination with gemcitabine for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy.

We wonder, where have those misleaders gotten their misleading information behind their prediction? It is hard to find out, as the true information was that **Phase 3 trial of Tarceva has shown a significant improvement in overall survival when added to gemcitabine chemotherapy in first-line pancreatic cancer.** As a matter of fact, Tarceva is the first new drug in nine years to have shown, in a randomized clinical trial, a statistically significant improvement in survival of patients suffering from advanced pancreatic cancer, a disease with a **very poor prognosis** for most patients. Yes, Tarceva was, indeed, the first drug since years to show improvement in the outcome of one of the nastiest cancers. It was hard for any reasonable person to believe that any Committee on the face of earth would reject the drug.

We congratulate those subscribers in Prohost who have been immunized against gossip and misleading conclusions. Those subscribers know by now the importance of Prohost's commonsense vaccine, which is protecting them from the ocean of hype investors sink in every single day.

Prohost subscribers know the history of Tarceva, as they have lived it with us since the firm's stock was trading at one digit. They know that Tarceva is an oral tablet before it has been approved for non-small cell lung cancer (NSCLC) for patients whose disease has progressed after one or more courses of chemotherapy. They know that some bearish do their best to nail stocks of firms that have successfully put blockbuster products on the market and they recognize most existing and upcoming blockbusters.

What about now? The FDA will review the ODAC recommendation and a decision on Tarceva approval is anticipated by **November 2, 2005**, i.e., in a month and a half.

We, again, congratulate Osi, Genentech and Prohost subscribers.

About the Study details: See press release, or CANCER NEWS on www.prohostonline.com.

BREAST CANCER

GENENTECH (DNA) .. AGAIN

A planned interim analysis of a Phase 3 trial of Herceptin® (Trastuzumab) plus chemotherapy in the adjuvant setting showed a **significant reduction in the risk of disease recurrence in women with early-stage (or cancer that has not spread beyond the breast and associated lymph nodes) human epidermal growth factor receptor 2 (HER2)- positive breast cancer.** The international study was supported by sanofi- aventis and Genentech, and conducted by the Breast Cancer International Research Group (BCIRG), who plans to submit the data to the San Antonio Breast Cancer Symposium (SABCS), December 8 to 11, 2005.



The trial evaluated three regimens as adjuvant therapy following initial treatment with surgery:

- * **doxorubicin and cyclophosphamide (AC) followed by Herceptin plus Taxotere® (docetaxel) chemotherapy (experimental arm)**
- * **Taxotere and carboplatin chemotherapies plus Herceptin (TCH) (experimental arm)**
- * **AC followed by Taxotere alone (control arm)**

Herceptin is a blockbuster and is the first drug to be prescribed only for a specific subtype of breast cancer patients whose cancer expresses *her2 neu*. Genentech's wisdom and courage is behind the decision to personalize the treatment. (See Prohost Newsletter)

This study differs from the two U.S. cooperative group trials presented at this year's American Society of Clinical Oncology (ASCO) meeting in that the BCIRG study included a novel regimen of Herceptin plus chemotherapy (TCH), enrolled both node-positive and node-negative patients, included Taxotere, and determined HER2 status by FISH (fluorescent in situ hybridization) testing.

No comment except that we congratulate the company and our subscribers on their courage and patience.

PROHOST RESEARCH
P.O. BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>